Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-05-17 Board/Management Inform…
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
8-K/A
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. The content specifically reports the election of a new board member and the assignment of that member to board committees. It does not contain financial statements or detailed financial performance data. The focus is on changes in the company's board of directors and their committee assignments. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3570 characters, which is consistent with a typical 8-K amendment filing for management changes. There is no indication that this is a full annual report, earnings release, or other financial report. Hence, the classification is MANG with high confidence.
2019-05-17 English
10-Q
Interim / Quarterly Report Q1 2019
2019-05-15 English
8-K/A
Regulatory Filings Classification · 100% confidence The document is a Form 8-K/A (Amendment No. 2) filed with the SEC, which is a current report amendment. It amends a previously filed Form 8-K by refiling certain exhibits (license agreements) with confidential information redacted. The document does not contain financial statements or detailed financial performance data, nor does it present earnings, management discussion, or other report types. It is an SEC regulatory filing updating previously filed information. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2019-05-13 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-05-10 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-27 English
FORM 3 SUBMISSION
Director's Dealing
2019-04-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.